However, the ability of RXFP1 to engage the JAK3‐STAT3 signaling pathway provides a hitherto underappreciated new route of promoting GBM invasiveness and, in part, may explain the limited treatment success of JAK2 inhibitors in malignant glioma. This evidence concerns the gene JAK3 and glioblastoma.